X
[{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Announces Bristol Myers Squibb opt-in of EVT8683 As the First Programme from iPSC-Based Neurodegeneration Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Reaches Programme Designations in Neuroscience Collaboration With Bristol Myers Squibb","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evotec"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The target-based programme designations further bolster the growing pipeline and are expected to follow EVT8683, which Bristol Myers Squibb opted to license after the successful filing of an IND application with the FDA.
Lead Product(s):
EVT8683
Therapeutic Area: Neurology
Product Name: EVT8683
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Bristol Myers Squibb
Deal Size: $40.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
November 10, 2021
Details:
Bristol Myers Squibb has enter into a global License Agreement for EVT8683. The programme targets a key cellular stress response mechanism which has the potential to deliver disease-modifying treatments for several devastating neurodegenerative diseases.
Lead Product(s):
EVT8683
Therapeutic Area: Neurology
Product Name: EVT8683
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Bristol Myers Squibb
Deal Size: $270.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
September 02, 2021